Will NICE Change Its Mind On Scenesse After UK Public Hearing?

 
• By Ian Schofield

This month should see the outcome of a public hearing held to discuss the decision by the UK's health technology assessment body, NICE, not to recommend funding for Clinuvel’s Scenesse, a novel treatment for the ultra-rare condition, erythropoietic protoporphyria.

Appeal
Clinuvel and patient groups are awaiting the outcome of their appeals against NICE's rejection of Scenesse • Source: Shutterstock

More from Market Access

More from Pink Sheet